The revolving door lobbying system in Washington allows former members of Congress and regulators to sell their government access to corporations immediately after leaving office — and it’s been quietly rigging American policy against younger generations for decades. In 2025, federal lobbying spending hit a record $5 billion, with industries like pharmaceuticals ($451.8M), defense ($293.3M), and Big Tech ($109M) using armies of former government insiders to write the laws that govern their own industries. The result: drug prices Americans can’t afford, wars that benefit contractors, regulations that protect incumbents, and a political system where your vote competes with a $5 billion lobbying budget — and loses.
Key Takeaways
- Federal lobbying spending hit a record $5 billion in 2025 — a 13% increase over 2024’s prior record of $4.44 billion
- 25% of House members and 29% of Senators eventually become registered lobbyists after leaving Congress
- 125 lobbyists moved from K Street to Congress in 2025 — a 60% increase over 2024
- Pharma alone spent $451.8 million lobbying in 2025; PhRMA hit a record $38 million on its own
- Defense lobbying hit $293.3 million in 2025 — up nearly 25% year-over-year, directly tied to Operation Epic Fury spending
- The Lobbying Disclosure Act’s 20% time threshold allows most lobbying activity to go unreported entirely
- Millennials carry 30% less wealth at age 35 than Boomers did at the same age — while the lobbying machine protected the policies that caused it
What Is the Revolving Door in Washington?
The revolving door describes the seamless career rotation between government positions and the private industries those officials were supposed to regulate or legislate. A congressman who spent six terms on the Senate Finance Committee retires and joins a pharmaceutical lobbying firm. An FDA regulator who approved a blockbuster drug gets hired by the company that made it. A Pentagon procurement officer who oversaw $80 billion in defense contracts goes to work for Lockheed Martin.
This isn’t corruption in the traditional sense — nobody’s being bribed in a parking garage. It’s legal. It’s disclosed (sort of). It’s rewarded. And that’s exactly what makes it so effective as a system for transferring regulatory power to private hands.
The mechanism is straightforward. A legislator spends years building relationships, learning the bureaucratic machinery, and accumulating favors. When they leave, those relationships are worth millions on the open market. A lobbyist with a former congressman’s cell phone number gets meetings that ordinary advocates can’t. A former FDA official who knows exactly how the drug approval process works is worth ten times a generic industry consultant to any pharmaceutical company looking to navigate that process.
The result is what political scientists call regulatory capture — the phenomenon where the agencies or legislators meant to regulate an industry end up serving that industry’s interests instead. It’s not a conspiracy; it’s a system that incentivizes compliance with corporate interests at every stage of a public servant’s career, because the private sector is watching — and hiring.
How Many Members of Congress Become Lobbyists?
The scale of Congress-to-lobbying pipeline is staggering once you look at the numbers directly. According to research published in the American Sociological Review, 25% of former House members and 29% of former Senators register as lobbyists after leaving Congress. That’s roughly one in four elected representatives eventually selling their congressional access back to the highest bidder.
And the traffic isn’t one-directional. In 2025 alone, 125 lobbyists moved from K Street back into congressional staff positions — a 59.74% increase over 2024’s figure of 78. Ninety-six former lobbyists were hired by partisan offices on Capitol Hill in the same period, with 64% working for Republican offices. The door doesn’t just revolve; it spins in both directions simultaneously, at increasing speed.
The financial incentive is unambiguous. A midlevel Senate staffer might earn $90,000-$130,000 a year. The same person, having spent six years building relationships with every committee member who matters on healthcare policy, can earn $500,000 to $2 million as a healthcare lobbyist within 12 months of leaving. It’s not a career change; it’s a monetization event.
A 2018 Washington Post investigation documented how many of the lawmakers and aides who crafted post-2008 financial regulations under Dodd-Frank subsequently moved to Wall Street. The people who wrote the rules that were supposed to constrain Wall Street were, within years, working for Wall Street. The same dynamic repeated with the Affordable Care Act, where many architects of healthcare reform migrated to healthcare industry lobbying firms.
Nine former members of Congress filed new lobbying registrations for the first time in 2025 — the same year total lobbying spending broke $5 billion. The correlation isn’t coincidental.
How Pharma Bought the FDA and Congress Simultaneously
The pharmaceutical industry revolving door operates at two levels: the regulatory (FDA) and the legislative (Congress), and the industry has learned to work both simultaneously. The result is drug prices that are three to ten times higher in the United States than in peer nations — a direct cost to younger Americans who can’t afford prescriptions, insulin, or mental health medications.
At the FDA level, the revolving door is well-documented. A 2023 Health Affairs study found that, on average, 15% of appointees to HHS-level healthcare agencies were employed by industry immediately before their appointment. Research published in Science found that FDA staffers who played pivotal roles in drug approvals — presenting evidence to advisory panels, influencing or making approval decisions — were regularly hired by the very companies whose drugs they reviewed.
At the legislative level, the numbers are even more stark. Pharma and health products companies spent $451.8 million on lobbying in 2025, making them the single largest industry lobby in Washington. That’s up from $384.5 million in 2024. PhRMA — the industry’s main trade group — alone spent a record $38 million in 2025. In the first quarter of 2026, lobbying firms with direct ties to the Trump administration pulled in $11.7 million from pharmaceutical company clients, up from $2.2 million in the prior year — a 432% increase.
The return on investment is extraordinary. The pharmaceutical industry has successfully blocked Medicare drug price negotiation for decades through lobbying. When the Inflation Reduction Act finally allowed limited Medicare drug price negotiation in 2022, it was a smaller, more compromised version than what advocates had sought — the product of years of pharma lobbying and the revolving door relationships that gave the industry access to the legislators writing the bill. Americans pay twice to three times more for the same medications as Canadians, Germans, or Australians. The revolving door is how that disparity gets locked in.
The Pentagon Revolving Door: When Generals Cash Out
The defense contractor revolving door is among the most normalized forms of institutional corruption in American life, perhaps because it operates under the cover of national security. When a four-star general retires and joins a defense contractor’s board of directors, it’s called “leveraging expertise.” When that general then lobbies their former colleagues at the Pentagon for contracts worth hundreds of millions of dollars, it’s called “consulting.”
A study by Responsible Statecraft found that 80% of retiring three- and four-star generals take positions with defense contractors or consulting firms within a year of leaving the military. The revolving door between the Pentagon and the weapons industry is so well-established that the Project on Government Oversight has tracked it annually for decades.
Defense lobbying spending hit $293.3 million in 2025 — a nearly 25% increase over the prior year. With Operation Epic Fury now consuming an estimated $1 billion per day in military expenditures, that lobbying investment has never looked more profitable. Lockheed Martin is up 39% since the Iran war began. Defense stocks soar while civilian retirement accounts crater — and the revolving door is what makes that asymmetry possible and permanent.
Rep. Warren Davidson introduced the “No Revolving Doors in Foreign Military Sales Act of 2025” specifically to address how former defense officials exploit their access to steer arms sales — a rare acknowledgment from within Congress that the problem is structural. It went nowhere. It always goes nowhere, because the committee members who would need to pass it have their own post-Congress employment prospects to consider.
The fiscal reality for younger taxpayers: the Pentagon’s contractor-driven budget has grown from $381.2 billion in FY2019 to $445.1 billion in FY2024 — a 16.8% increase in five years, driven significantly by the lobbying-industrial complex that the revolving door created and maintains.
Why the Lobbying Disclosure Act Is a Joke
The Lobbying Disclosure Act of 1995 was supposed to bring transparency to the influence industry. Thirty years later, it’s widely recognized as one of the most effectively circumvented transparency laws in American government — and deliberately so.
The LDA’s core flaw is its 20% time threshold: you only have to register as a lobbyist if lobbying constitutes 20% or more of your time on behalf of any single client. This created the category of “shadow lobbying” — where former officials conduct essentially the same work (scheduling meetings with former colleagues, drafting legislative strategy, attending committee hearings) while spending just enough time on other tasks to stay under the 20% threshold. The Campaign Legal Center estimates that tens of thousands of people who function as lobbyists never register as such.
The monetary thresholds are equally toothless. As of 2025, the LDA only requires organizations that employ lobbyists to register if they spend more than $16,000 per quarter on lobbying. For a Fortune 500 company trying to shape a major regulatory decision worth hundreds of millions, spending under that threshold is trivial — and legally allows them to conduct influence operations that never appear in any public disclosure.
A 2024 GAO audit found that 21% of quarterly lobbying reports contained inaccuracies. The enforcement mechanism for violations is essentially an honor system — the Department of Justice is supposed to pursue civil penalties against violators, but prosecutions are vanishingly rare. In the entire history of the LDA, criminal prosecutions for non-compliance have numbered in the single digits.
Meanwhile, the 2010 Citizens United ruling opened a separate channel — dark money through 501(c)(4) organizations — that allows unlimited undisclosed corporate spending to influence elections and policy. The LDA was already a paper tiger; Citizens United made it irrelevant for the largest players in the game.
How Revolving Door Lobbying Transfers Wealth from Young to Old
The revolving door lobbying system’s impact on millennials and Gen Z isn’t abstract. Every major policy failure that has suppressed younger Americans’ economic mobility has been maintained — and in many cases created — by the lobbying-industrial complex.
Drug prices remain the highest in the developed world because pharma’s revolving door lobbyists killed Medicare negotiation for 20 years. Medical debt is the leading cause of personal bankruptcy in America — a direct function of a healthcare pricing system designed by and for an industry that has spent $451 million per year protecting it.
The Glass-Steagall repeal — which allowed banks to combine commercial and investment functions and ultimately contributed to the 2008 financial crisis — was the product of years of financial industry lobbying. The Gramm-Leach-Bliley Act was drafted with significant input from financial industry lobbyists, many of them former government officials. When the crisis hit, it was the Millennial generation entering the workforce who absorbed the economic damage: graduating into the worst job market in 70 years, with student debt, no 401k, and a housing market that had been permanently distorted.
The CFPB — created by Dodd-Frank to protect consumers from the exact financial industry abuses that caused the crisis — has now been gutted by $19 billion in rollbacks, driven by financial industry lobbying that began the day Dodd-Frank was signed. The revolving door ensures that the people executing those rollbacks are often the same people who left government to join the financial sector, then returned to government with a new set of priorities.
The aggregate result: the average Millennial has 30% less wealth at age 35 than Baby Boomers had at the same age, according to research from the Federal Reserve. Younger Americans are on the hook for approximately $73 trillion in unfunded government obligations over the next 75 years — Social Security, Medicare, defense spending, debt service — programs and expenditures that have been protected and expanded by the revolving door lobbying system for decades, with the bill forwarded to people who weren’t old enough to vote when the decisions were made.
Counter-Argument: ‘Lobbying Is Just Free Speech’
The standard defense of the revolving door system rests on two arguments: that lobbying is constitutionally protected free speech and association, and that former officials bring valuable expertise that improves policymaking. Both have merit — and both are true as far as they go.
The First Amendment protects the right to petition government. Lobbying is, in its idealized form, a legitimate mechanism for conveying information about complex policy questions to legislators who can’t be experts in everything. A pharmaceutical company explaining the drug approval process to a Senate staffer genuinely helps that staffer write better regulation. A defense contractor briefing the Armed Services Committee on the technical specifications of a next-generation weapon system provides real information value.
The problem isn’t the information exchange — it’s the access asymmetry. When pharmaceutical companies can place former FDA officials on their payroll to navigate regulatory processes, they are not simply providing information; they are buying preferential access to a process that their competitors cannot afford to influence equally. When a retired senator can get a committee chairman on the phone in ten minutes because they served together for 15 years, that’s not expertise — it’s relationship monetization that no citizen voter or small-business owner can replicate.
European democracies with stricter revolving door rules — France requires a three-year cooling-off period for many officials; Germany requires senior officials to notify the government of post-employment offers — do not appear to suffer from less well-informed policymaking. The EU’s approach demonstrates that the “expertise” argument, while real, does not require the specific monetization structure that the American revolving door provides. Expertise can be retained; the pay-to-play access structure does not have to come with it.
Frequently Asked Questions
What is the revolving door in politics?
The revolving door in politics refers to the movement of individuals between government positions (as legislators, regulators, or staffers) and private sector roles in the industries they previously regulated or legislated. In the United States, 25% of former House members and 29% of former Senators eventually register as lobbyists, monetizing relationships and institutional knowledge built at taxpayer expense.
Is the revolving door in Washington legal?
Yes, with limited restrictions. Federal law requires a one-year cooling-off period for senior executive branch officials before they can lobby their former agency, and two years for very senior officials. Members of Congress face a one-year (Senate) or two-year (House) cooling-off period. However, during the cooling-off period, former officials can still conduct “strategic consulting,” advise lobbying firms, and perform work that functions as lobbying without technically qualifying as such under the Lobbying Disclosure Act’s narrow definition.
How much money is spent on lobbying in the US?
Federal lobbying spending hit a record $5 billion in 2025, according to OpenSecrets. That is up from $4.44 billion in 2024, which was itself a record. The pharmaceutical and health products industry is the largest single lobby, spending $451.8 million in 2025. Defense lobbying reached $293.3 million in 2025, up nearly 25% from the prior year. Big Tech companies collectively exceeded $100 million in lobbying spending for the first time in 2025.
What reforms would fix the revolving door problem?
Reform proposals typically focus on four areas: (1) extending cooling-off periods to three to five years for senior officials across all branches; (2) lowering the Lobbying Disclosure Act’s 20% time threshold to 5-10% to capture shadow lobbying; (3) banning members of Congress from ever becoming lobbyists (a lifetime ban exists for lobbying on specific matters they were involved in, but not a general prohibition); and (4) creating an independent enforcement body with real prosecution authority for LDA violations. None of these reforms have passed Congress, in no small part because the people who would need to pass them are the people who benefit from the current system.
Sources & Methodology
Data in this article draws from OpenSecrets federal lobbying data (2024–2025); LegiStorm revolving door tracking (2025); research published in the American Sociological Review (Lazarus, McKay, and Herbel 2016) on post-congressional employment; Health Affairs (2023) on HHS revolving door appointees; Statista U.S. total lobbying spending 1998–2025; Bloomberg reporting on Big Tech lobbying spending 2025; Responsible Statecraft and POGO on Pentagon revolving door statistics; Campaign Legal Center analysis of LDA weaknesses; GAO 2024 lobbying disclosure audit; Federal Reserve research on millennial wealth gaps; and LA Times/Brookings reporting on generational unfunded obligations. All lobbying spending figures reflect registered federal lobbying expenditures as reported to the House Clerk and Senate Office of Public Records under the Lobbying Disclosure Act.
